

Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador

Paris and Boston, November 20, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, is pleased to announce that Dr. Carlos Robles-Medranda, and his dedicated team at the *Instituto Ecuatoriano de Enfermedades Digestivas y Pélvicas* (IECED) located within OMNI Hospital in Guayaquil, Ecuador, achieved a significant milestone. Over the past 18 months, this skilled medical team has successfully performed more than 700 advanced endoscopic procedures utilizing the Cellvizio® platform, demonstrating the value of this technology in supporting accelerated detection and diagnosis, and guiding informed treatment for patient care using high-quality, real-time, in vivo cellular imaging.

The IECED-OMNI Hospital (<https://ieced.com.ec>), internationally renowned for its expertise in digestive and pelvic disease management, is a key player of Ecuador's Endoscopy Network—a comprehensive healthcare network operating over 10 top-tier facilities nationwide and a world-renowned training center for interventional endoscopists, endorsed by the World Endoscopy Organization (WEO). Under the leadership of Dr. Robles-Medranda, a respected expert in therapeutic endoscopy, the IECED team has adopted and integrated the Cellvizio® platform into routine clinical practice in the field of gastroenterology, allowing for improved diagnostic accuracy and more targeted therapeutic interventions.

“Confocal Laser Endomicroscopy is a key adjunct to our endoscopy armamentarium at IECED, addressing a variety of indications in gastroenterology”, declared Dr. Carlos Robles-Medranda, Director General of IECED. “For pancreatic cyst and biliary stricture characterization, early gastric cancer detection or identification of previously undetectable food intolerances, endomicroscopy plays a vital role for our physicians and patients. I have been a user and developer of endomicroscopic applications for more than a decade and could not be more thrilled to see how this technology has taken a key role in these indications. We continuously explore new ways to use this unique technology in combination with other platforms and AI.”

Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies added: *“We are very proud to see renowned experts like Dr. Robles-Medranda adopt and utilize our platform so extensively across diverse clinical applications, underscoring the unique value of Cellvizio in the daily practice of many physicians and its capability to handle high volumes. I am very excited to see this adoption expand further, in particular in South America where IECED plays a key role.”*

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used

globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.

Mauna Kea Technologies

investors@maunakeatech.com

NewCap - Investor Relations

Aurélie Manavarere / Thomas Grojean
+33 (0)1 44 71 94 94
maunakea@newcap.eu

Disclaimer

This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2023 Annual Report filed with the *Autorité des marchés financiers* (AMF) on April 30, 2024, which is available on the Company's website (www.maunakeatech.fr), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.